ArticleTranslational vision science & technology2025
Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Challenges of Managing Fibrosis Post Glaucoma Surgery and Future Perspectives.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate different routes of valproic acid (VPA) administration in modulating various phases of wound healing events after minimally invasive bleb surgery (MIBS). Methods: Thirty New Zealand White rabbits underwent surgical implantation of PRESERFLO MicroShunts. Animals were divided into treatment groups of mitomycin C (MMC) 0.4 mg/mL, MMC 0.1 mg/mL, VPA 1 mg/mL, and VPA 30 mg/mL. Treatments with topical and subconjunctival administration were investigated in the combination groups of low-dose MMC (0.1 mg/mL) and VPA. IOP was measured and slit-lamp photographs were taken weekly. Fibrotic gene expression was analyzed in the bleb by quantitative polymerase chain reaction and western blot. Histology was performed following sacrifice on day 28. Results: Low-dose MMC (0.1 mg/mL) combined with VPA resulted in prolonged bleb survival to day 28. This was associated with reduced collagen 1 and fibronectin gene and protein expression (P < 0.05). There was also a favorable extracellular matrix structure on histological analysis due to the presence of fine immature collagen fibrils surrounding the shunt opening. Intraocular pressure lowering was seen, with a reduction of 20% from baseline IOP until day 14. Both topical and subconjunctival administration of VPA demonstrated similar outcomes, with no overt side effects observed throughout the experimental period at different doses or dosing regimens. Conclusions: VPA is a versatile and effective adjunctive agent that can be used in combination with low-dose MMC to produce favorable bleb characteristics in MIBS. Translational Relevance: VPA is both efficacious and safe as an antifibrotic agent, and different routes of administration are available to target different stages of fibrosis after filtration surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.